A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer

作者：Kote Jarai Z; Jugurnauth S; Mulholland S; Leongamornlert D A; Guy M; Edwards S; Tymrakiewitcz M; O'Brien L; Hall A; Wilkinson R; Al Olama A A; Morrison J; Muir K; Neal D; Donovan J; Hamdy F; Easton D F; Eeles R^*

来源：British Journal of Cancer, 2009, 100(2): 426-430.

DOI：10.1038/sj.bjc.6604847

• prostate cancer predisposition
• FANCJ/BRIP1
• deleterious mutation
• SNPs

Although prostate cancer (PrCa) is one of the most common cancers in men in Western countries, little is known about the inherited factors that influence PrCa risk. On the basis of the fact that BRIP1/FANCJ interacts with BRCA1 and functions as a regulator of DNA double-strand break repair pathways, and that germline mutations within the BRIP1/FANCJ gene predispose to breast cancer, we chose this gene as a candidate for mutation screening in familial and young-onset PrCa cases. We identified a truncating mutation, R798X, in the BRIP1/FANCJ gene in 4 out of 2714 UK PrCa cases enriched for familial (2 out of 641; 0.3%) and young-onset cases (2 out of 2073; 0.1%). On screening 2045 controls from the UK population, we found one R798X sequence alteration (0.05%; odds ratio 2.4 (95% CI 0.25-23.4)). In addition, using our data from a genome-wide association study, we analysed 25 SNPs in the genomic region of the BRIP1/FANCJ gene. Two SNPs showed evidence of association with familial and young-onset PrCa (rs6504074; P(trend) = 0.04 and rs8076727; P(trend) = 0.01). These results suggest that truncating mutations in BRIP1/FANCJ might confer an increased risk of PrCa and common SNPs might also contribute to the alteration of risk, but larger case-control series will be required to confirm or refute this association.

• 出版日期2009-1-22